Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.71 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.71 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19278471 | 0.96 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL19260272 | 0.91 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL20548115 | 0.89 | HDAC6 (0.87) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL19278560 | 0.86 | HDAC1 (0.75) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL19260229 | 0.84 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL19260278 | 0.83 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL25058872 | 0.82 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL28633676 | 0.82 | HDAC1 (0.95) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL19278472 | 0.81 | HDAC1 (0.75) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL23950253 | 0.81 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416633-B1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | UNIV ILLINOIS (US) | 2025-07-23 | — | — | EP | disclosed |
| US-10456394-B2 | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-10-29 | — | — | US | disclosed |
| US-10456394-B2 | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190255046-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOS (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190255046-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOS (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3416633-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | The Board of Trustees of the University of Illinois (US) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017142883-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017142883-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255046-A1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | HDAC1, HDAC5, HDAC7 | HDAC1 1/4885HDAC6 8/4885HDAC8 4/4885 |
| US-10456394-B2 | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors | HDAC1, HDAC5, HDAC7 | HDAC1 1/4885HDAC6 8/4885HDAC8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.